Nabiximols spray was feasible and safe for treating agitation in Alzheimer's patients

In a randomized, double-blind, placebo-controlled feasibility trial, 29 nursing home residents with Alzheimer's disease and clinically significant agitation were randomized to nabiximols or placebo for 4 weeks. No participants withdrew, adherence was 100%, and the intervention was well tolerated with zero adverse reactions reported. While the recruitment target of 60 was not met due to COVID-19 challenges, the trial demonstrated that administering oral mucosal spray to advanced AD patients with agitation was generally feasible.

Randomized, double-blind, placebo-controlled feasibility study (STAND trial) in UK care homes. Participants with probable Alzheimer's disease and predefined clinically significant agitation were randomized to nabiximols or placebo for 4 weeks on an up-titrated schedule, followed by 4-week observation. Prespecified feasibility thresholds assessed.

Agitation in Alzheimer's disease causes significant distress and currently available treatments have limited efficacy with substantial side effects. This feasibility trial establishes that a cannabinoid-based approach can be safely delivered in nursing home settings, clearing the path for larger efficacy trials.

Agitation is one of the most challenging behavioral symptoms in dementia care, often leading to antipsychotic prescribing despite known risks. Cannabinoid-based alternatives could fill a significant treatment gap if efficacy trials confirm the safety signals from this feasibility study.

Feasibility study not powered for efficacy outcomes. Did not meet recruitment target (29 of 60) due to COVID-19. Short 4-week treatment period. UK nursing home setting may not generalize to other care contexts. Efficacy remains unproven.